Confo Therapeutics

Confo Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel medicines that target G protein-coupled receptors (GPCRs). The company's unique technology platform utilizes conformationally selective VHH antibodies, known as ConfoBodies®, to stabilize GPCRs in disease-relevant conformations, enabling the identification of highly specific and potent drug candidates. Confo Therapeutics has a robust pipeline of small molecules and antibodies for various indications, with a particular focus on endocrine and metabolic diseases.

Confo Therapeutics has garnered significant recognition for its innovative approach, including being named one of Fierce Biotech's "Fierce 15" biotech companies of 2019 and receiving the 2019 EuropaBio Awards in the Healthcare Biotech category. They have also secured funding from a strong consortium of global investors and have established partnerships with leading pharmaceutical companies like Eli Lilly and Daiichi Sankyo, demonstrating the potential of their technology and the company's commitment to developing transformative medicines for patients with severe illnesses.

Confo Therapeutics is a clinical-stage biotechnology company dedicated to developing novel medicines targeting G protein-coupled receptors (GPCRs), the largest and most diverse group of membrane receptors in the human body. Their mission is to unlock the therapeutic potential of GPCRs by using their proprietary technology to stabilize the receptors in their functionally relevant states, thereby enabling the discovery and development of breakthrough medicines that address a wide range of severe illnesses, particularly those with high unmet medical needs. They are focused on building a pipeline of both small molecules and therapeutic antibodies to transform therapeutic outcomes for patients, with a particular focus on endocrine and metabolic diseases.

Confo Therapeutics fosters a collaborative and innovative culture, attracting a diverse team of experienced scientists and business professionals from around the world. The company values its employees' expertise and fosters a strong team spirit, emphasizing a dedication to scientific excellence and the development of groundbreaking therapies to address unmet medical needs.

Confo Therapeutics fosters a culture of inclusion and diversity, valuing the unique perspectives and experiences of all employees. Their commitment to building a diverse and equitable workforce is reflected in their recruitment practices and internal initiatives that promote equal opportunities and foster a welcoming environment where every voice is heard and respected. The company actively seeks to attract and retain top talent from diverse backgrounds, ensuring a more inclusive and vibrant work environment.